• Home
  • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Fortune 500
    • Fortune 500 U.S.
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
  • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  • Home
  • Latest
    • Latest
    • News
    • North America
    • Europe
    • Asia
    • Middle East
    • Global
  • Fortune 500
    • Fortune 500
    • Fortune 500 U.S.
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
  • Finance
    • Finance
    • Economy
    • Banking
    • Personal Finance
    • Investing
    • Real Estate
    • Energy
    • Crypto
  • Tech
    • Tech
    • Big Tech
    • Startups & Venture
    • AI
    • Innovation
    • Cybersecurity
  • Leadership
    • Leadership
    • Future Of Work
    • Success
    • C-Suite
    • Workplace Culture
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Health
    • Travel & Leisure
    • Education
  • Rankings
    • Rankings
    • Great Place To Work
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Press Releases
    • Video
    • Podcasts
  1. home
  1. home
  2. Pharmaceutical Industry

Pharmaceutical Industry

Page 93 of 100

Pharma M&A boom rolls on: now Celgene’s buying Receptos
Tech

Pharma M&A boom rolls on: now Celgene’s buying Receptos

By Geoffrey Smith
July 15, 2015
Vida Health and AstraZeneca launch new app for post-heart attack recovery
Tech

Vida Health and AstraZeneca launch new app for post-heart attack recovery

By Laura Lorenzetti
July 14, 2015
Meet BioBot, the ‘MakerBot of biology’
Tech

Meet BioBot, the ‘MakerBot of biology’

By Andrew Zaleski
July 13, 2015
Novartis senses a blockbuster after FDA approves its new heart drug
Tech

Novartis senses a blockbuster after FDA approves its new heart drug

By Geoffrey Smith
July 9, 2015
CVS Health leaving U.S. Chamber of Commerce over smoking spat
Retail

CVS Health leaving U.S. Chamber of Commerce over smoking spat

By Phil Wahba
July 8, 2015
Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival
Finance

Ireland’s Horizon Pharma launches hostile, $3 billion bid for U.S. rival

By Tom Huddleston Jr.
July 7, 2015
186815051
Tech

Despite regulatory troubles, DNA testing firm 23andMe raises more money

By Kia Kokalitcheva
July 2, 2015
These are the Fortune 500’s fastest-growing pharma companies
Features

These are the Fortune 500’s fastest-growing pharma companies

By Laura Lorenzetti
June 20, 2015
The 10 Biggest Health Care Companies in the Fortune 500
Features

The 10 Biggest Health Care Companies in the Fortune 500

By Laura Lorenzetti
June 20, 2015
These Fortune 500 companies leapfrogged the rest
Finance

These Fortune 500 companies leapfrogged the rest

By Kia Kokalitcheva
June 19, 2015
Flibanserin
Features

A female Viagra is one step closer to reality

By Laura Lorenzetti
June 4, 2015
Food and Farm Livestock Antibiotics
Retail

Antibiotics in meat: A public health controversy that isn’t going away

By Mark Koba
June 3, 2015
Bristol-Myers Squibb R&D headquarters
Tech

New cancer drug combo shrinks tumors in 60% of patients – study

By TIME and Fortune Editors
June 1, 2015
19 kids and cancelled: TV shows that got pulled due to controversy
Arts & Entertainment

19 kids and cancelled: TV shows that got pulled due to controversy

By Daniel Bukszpan
May 28, 2015
Can Gilead keep growing without a big deal?
Finance

Can Gilead keep growing without a big deal?

By Jen Wieczner
May 23, 2015

Most Popular

  • Economy
    Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House post
    By Eleanor Pringle
  • Success
    In 2026, many employers are ditching merit-based pay bumps in favor of ‘peanut butter raises’
    By Emma Burleigh
  • Investing
    Tech stocks go into free fall as it dawns on traders that AI has the ability to cut revenues across the board
    By Jim Edwards
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Fortune
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.